A new analysis of two large HIV prevention trials is a reminder that stopping a long-acting prevention tool matters as much as starting it. Published November 4, 2026 in Science Translational Medicine, the final week-104 results from the Antibody Mediated Prevention (AMP) trials show that an investigational antibody called VRC01, given by intravenous infusion, kept blocking HIV strains that were highly sensitive to it. But after the infusions ended, more infections with VRC01-resistant virus showed up in the antibody groups than in the placebo groups. The authors conclude that a single antibody is not enough and that combinations will likely be needed.

VRC01 is not a prevention option you can get, and nothing here changes how approved HIV prevention or treatment works. Still, the findings help explain where long-acting HIV prevention research is heading, and they are worth understanding if you are dating, have a partner with a different HIV status, or follow PrEP news.

The short version

• What was studied: VRC01, a broadly neutralizing antibody first found in the blood of a person living with HIV, given as 10 intravenous infusions over 80 weeks (about every 8 weeks) in two phase 2b trials, according to the NIH.
• The good news: Against viruses considered highly sensitive to VRC01, prevention efficacy held at 66.3% (95% confidence interval 32.4% to 83.2%) through the week-104 final visit, per the new paper.
• The catch: In the period after week 80 (the last dose was at week 72), HIV diagnoses and resistance to VRC01 were more frequent and greater in the VRC01 groups than in the placebo groups. For example, 11 versus 1 diagnoses involved viruses moderately sensitive or resistant to VRC01.
• The takeaway: Single antibodies can block sensitive strains, but multiple antibodies are likely needed to prevent both viral escape and breakthrough infections, the authors write.

What the AMP trials were

The AMP studies, sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), enrolled more than 4,600 people without HIV. According to the NIH's 2021 announcement of the first results, one trial (HVTN 704/HPTN 085) enrolled 2,699 cisgender men and transgender people who have sex with men in Brazil, Peru, Switzerland and the United States. The other (HVTN 703/HPTN 081) enrolled 1,924 cisgender women in seven sub-Saharan African countries. Participants were randomly assigned to VRC01 at one of two doses or to placebo, and neither participants nor investigators knew who received which.

In 2021, the headline was mixed. VRC01 prevented acquisition of HIV strains that were sensitive to it, with about 75% efficacy against those strains, but it did not significantly reduce overall HIV acquisition at 80 weeks. NIH investigators attributed that to the fact that only about 30% of the HIV strains circulating in the study regions were sensitive to VRC01. Larry Corey, the AMP protocol chair for the HIV Vaccine Trials Network, said then that "more than one antibody likely will be needed to offer effective protection against the wide variety of HIV strains, similar to how combinations of antiretroviral drugs are required to treat HIV."

What the new week-104 analysis adds

The 2021 results covered the 80-week infusion period. The new paper, led by Allan deCamp and colleagues, follows participants through the final study visit at week 104, which gives a look at what happens as the antibody wears off. Per the published abstract:

• Against viruses considered highly sensitive to VRC01, the antibody maintained a cumulative prevention efficacy of 66.3%, which the authors say suggests it successfully blocked or cleared those infections.
• After week 80, HIV diagnosis and resistance to VRC01 were more frequent and greater in the VRC01 groups than in the placebo groups.
• Diagnoses with viruses considered moderately sensitive or resistant to VRC01 numbered 11 in the VRC01 groups versus 1 in the placebo groups.

The authors offer a plausible explanation: as the amount of antibody in the body dropped, viruses that had been suppressed, often while evolving greater resistance under the antibody's selective pressure, emerged as detectable infections. A summary distributed by the American Association for the Advancement of Science adds that the results matter for how future antibody trials are designed, including the importance of testing for HIV long after infusions have ended.

It is important to keep this in proportion. This was an analysis of an investigational, intravenous antibody that is not approved for HIV prevention. It does not show that approved PrEP products have the same pattern, and it does not say anything about how HIV treatment or U=U (Undetectable = Untransmittable) works.

Why researchers care about antibodies at all

Broadly neutralizing antibodies are designed to stop HIV from infecting cells in the first place. The NIH has described them as promising candidates for long-acting prevention because they could be given by infusion or injection, or one day elicited by a vaccine. The AMP trials were among the most advanced efficacy tests of the idea, and they produced a laboratory method to predict how well an antibody will work against different HIV strains. The new data reinforce what researchers have been saying since 2021: the field is moving toward combinations of potent, long-lasting antibodies rather than any single one.

What this means if you are dating

Nothing in this study asks anyone to change how they date, disclose or protect themselves. A few grounded points:

• U=U is unaffected. People living with HIV who take treatment as prescribed and keep a sustained undetectable viral load have effectively no risk of sexually transmitting HIV. Our guide to undetectable viral load and U=U explains what that means in a relationship.
• PrEP options already exist. The CDC describes PrEP as medicine, pills or shots, that greatly reduces the chance of getting HIV from sex or injection drug use, and notes that it does not prevent other STIs or pregnancy. For recent developments in long-acting shots, see our posts on the first generic twice-yearly PrEP shot and the global push to expand access.
• Prevention works best as a plan. Our explainer on what PrEP and DoxyPEP do not protect against covers testing, vaccines and condoms alongside medicines.
• Couples with different statuses have more tools than ever. Read our piece on serodiscordant couples for relationship-focused guidance.

Decisions about prevention, including which option fits and how to stop one safely, belong with a licensed clinician who knows your health history.

Quick FAQ

Is VRC01 available as HIV prevention?
No. It is an investigational antibody that was studied in clinical trials. This article does not recommend or promote any product.

Does this mean PrEP stops working when you stop taking it?
No. This analysis concerns one investigational antibody given by infusion and the strains that broke through as its levels fell. It does not describe approved PrEP. People who are thinking about stopping PrEP should talk with their health care provider, as the CDC advises, about how to do so safely and what other prevention options may fit.

Does this change U=U?
No. U=U is based on HIV treatment that keeps the virus undetectable in people living with HIV. These trials tested a prevention antibody in people without HIV.

Why do researchers say combinations are needed?
Individual antibodies can be escaped by resistant virus. The authors conclude multiple antibodies are likely required to prevent both viral escape and breakthrough infections, similar to how HIV treatment uses combinations of drugs, as NIH investigators noted in 2021.

The bottom line

The final AMP data show both the promise and the limits of antibody-based HIV prevention: strong protection against sensitive strains while the antibody was present, and more resistant breakthroughs after it faded. For people dating with or without HIV today, the practical message has not changed: effective treatment, U=U, existing PrEP options, testing and honest conversations remain the foundation. If you are looking for a community that understands life with HIV or another STI, explore HIV dating on MeetPositives.

Sources

• deCamp AC, et al. "Extended in vivo activity of VRC01 HIV-1 prophylaxis entails initial protective efficacy and subsequent breakthrough infections." Science Translational Medicine 18(874), November 4, 2026. DOI: 10.1126/scitranslmed.aec3480.
• National Institutes of Health. "Antibody infusions prevent acquisition of some HIV strains, NIH studies find." January 26, 2021.
• Centers for Disease Control and Prevention. "Preventing HIV with PrEP." Updated September 15, 2026.

This article is for general information only and is not medical advice. It does not create a doctor-patient relationship. Talk with a licensed health care provider about your own situation.